As part of its plan to focus on its core assets, Novartis has sold its global influenza vaccines business to Australia's CSL for $275 million. Earlier this year, GlaxoSmithKline paid $5.25 billion plus potential milestone payments and royalties for Novartis' vaccines business, excluding flu. CSL plans to combine the Novartis unit with its bioCSL subsidiary to create the second-largest supplier in the $4-billion global flu vaccine industry. The deal is expected to close in the second half of 2015, pending regulatory approval.
Rights and permissions
About this article
Cite this article
Novartis unloads flu vaccine unit. Nat Biotechnol 32, 1177 (2014). https://doi.org/10.1038/nbt1214-1177c
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt1214-1177c